Taking into consideration that normal breast-like tumors do not respond to neoadjuvant chemotherapy as well as basal-like cancers do [23], the identification by p53 of the subset of patients that could benefit from an adjuvant anthracyclines/alkylating agent-based chemotherapy is great clinical relevance. Here, TP53 is linked to cancer.